RESTORE-1 Clinical Study
AN EXPERIMENTAL, ONE-TIME GENE THERAPY FOR PARKINSON’S DISEASE
RESTORE-1 is a clinical study for people with advancing Parkinson’s disease.
If your response to Parkinson’s disease medications has become unpredictable or isn’t what it used to be, this clinical study may be an option that you should discuss with your doctor. The RESTORE-1 Clinical Study is evaluating an experimental, one-time gene therapy approach to see if it may help improve motor function.
You may be eligible to participate if you:
- Are 40 to 75 years of age (inclusive)
- Have been diagnosed with Parkinson’s disease for at least four years
- Are able and willing to travel and take part in extended study visits, including off-medication visits
- Have noticed your motor symptoms are unpredictable despite medication
- Agree to defer any neurological surgery, including deep brain stimulation (DBS), other invasive treatments for PD including Duopa, or the addition of new dopaminergic formulations until after completing the 12-month study visit